On Jan. 11, 2021, TheNew York Times posted an article about the virtues of fecal immunochemical testing relative to colonoscopy. The story, “A Colonoscopy Alternative Comes Home” [https://www.nytimes.com/ 2021/ 01/ 11/ health/ colonoscopy-health-home-testing.html] depicted colonoscopy as a comparatively risky procedure with few advantages over less invasive methods of testing for colorectal cancer. It also offered the speculation that financial factors— namely, greater reimbursement for endoscopy—was behind the general preference of gastroenterologists for colonoscopy over stool tests.
Trending
- Is This the AI Endgame? What Happens to GI?
- The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb
- Medicare to cover colorectal cancer screenings ordered by PAs, APRNs (Becker’s GI & Endoscopy)
- America Is Running Out of Doctors (The Health Care Blog)
- Weighed Down by Paperwork: Identifying Barriers to Metabolic and Bariatric Surgery Evaluation in the United States (Springer Nature)
- Banning Corporate Medicine: Stopping Private Equity’s Debt Trap (Forbes)
- Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal (The New England Journal of Medicine)
- Blood test targets ‘Achilles’ heel’ of CRC screening, detects 81% of advanced adenomas (Healio)
